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Background: A relapse prevention program called the Information Technology Aided Relapse Prevention Pro-
gramme in Schizophrenia (ITAREPS) has been developed and is reported to be highly effective. However the
effectiveness was inﬂuenced by user adherence to the protocol of the program, the exact effectiveness and the
role of the ITAREPS have been partially uncertain.
Objective: The purpose of this study is to evaluate the effectiveness of the ITAREPS excluding the effect of user
adherence to the protocol of the program.
Method:We attempted to perform a randomized controlled trial by the devised method with visiting nurse ser-
vice. Outpatients with schizophrenia were randomized to the ITAREPS (n = 22) or control group (n = 23) and
were observed for 12 months.
Results: The risk of rehospitalization was reduced in the ITAREPS group (2 [9.1%]) compared with the control
group (8 [34.8%]) (hazard ratio = 0.21, 95% CI 0.04–0.99, p = 0.049; number needed to treat (NNT) = 4, 95%
CI 2.1–35.5). The mean number of inpatient days was signiﬁcantly lower in the ITAREPS group (18.5 days) com-
pared with the control group (88.8 days) (p = 0.036). The ratio of the number of rehospitalizations to that of
relapses was signiﬁcantly lower (p = 0.035) and the mean change in total BPRS scores at relapse from baseline
was signiﬁcantly less in the ITAREPS group (p = 0.019).
Conclusions: The relapse prevention effectiveness of the ITAREPS was high, and we conﬁrmed that the ITAREPS,
i.e., detecting signs of relapse and increasing medication during the warning state, is an effective intervention
during the early stages of relapse.© 2013 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-SA license. 1. Introduction
Schizophrenia often follows a chronic course.Many patients respond
to early antipsychotic drug therapy, but 80% relapse within 5 years of
onset (Robinson et al., 1999). Repeated relapses lead to worsening of81 43 226 2150.
u).
.Open access under CC BY-NC-SA licenprognosis, such as poorer response to treatment (McGlashan, 1988), or-
ganic changes in the brain (Mathalon et al., 2001), and increased suicide
rate (Wiersma et al., 1998). Therefore, preventing relapses and
rehospitalization are extremely important for patients with schizophre-
nia. Recent systematic reviews have shown that antipsychotic drug
therapy can reduce the recurrence rate of schizophrenia (Leucht et al.,
2012). However, this therapy is often interrupted because of patient
compliance and side effects (Keith, 2006); antipsychotic drug therapy
strategies for the maintenance phase of schizophrenia are not well
established (Takeuchi et al., 2012).
A relapse prevention program called the Information Technology
Aided Relapse Prevention Programme in Schizophrenia (ITAREPS) hasse. 
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2008a, 2008b). The ITAREPSpresents amobile phone-based telemedicine
solution for weekly remote patient monitoring and disease management
in schizophrenia and psychotic disorders in general. The program pro-
vides health professionals with home telemonitoring via a PC-to-phone
short message service (SMS) platform that identiﬁes prodromal symp-
toms of relapse, to enable early intervention and prevent unnecessary
hospitalizations. Participants enrolled in the ITAREPS (the patient and
her/his family member) were instructed to complete a 10-item Early
Warning Sign Questionnaire (EWSQ) by a short message service (SMS)
request sent weekly by an automated system to their mobile phones. At-
tendance of a family member at the ITAREPS was highly recommended,
albeit optional. Reporting on psychometric properties and structure of
EWSQ has been published elsewhere (Španiel et al., 2008a, 2008b). Indi-
vidual EWSQ scores were sent by participants back to the ITAREPS as an
SMS. If a total EWSQ score exceeds a given score threshold, an automati-
cally generated ALERT is declared and a treating psychiatrist is notiﬁed by
an e-mail message. According to a speciﬁc procedure, the presence of
early warning signs warrants an immediate increase in baseline mainte-
nance dose of antipsychotic by 20% within the next 24 h. Once an ALERT
was declared, it continued for the next 3 week ALERT PERIOD, providing
that the following 6 consecutive EWSQ scores showed no worsen-
ing of symptoms. If so, the ALERT PERIOD was withdrawn and the
event announced to psychiatrist via e-mail along with recommen-
dation concerning subsequent tapering down of the medication to
the pre-ALERT dose. During the ALERT PERIOD, patients were to re-
turn answered questionnaires twice weekly upon SMS request. In
addition to that, more conservative score thresholds were adopted.
If EWSQ scores exceeded those modiﬁed thresholds anytime during
the ALERT PERIOD, an ALERT EMERGENCY was announced via e-
mail. In such a case the ALERT PERIOD was extended for a further
3 weeks after each ALERT EMERGENCY message. Thus, by incorpo-
rating information technology, this program is a method to prevent
relapse by predicting early signs and administering pharmacologi-
cal intervention. As a result of introducing this new relapse preven-
tion program, a before-and-after 2-year comparative study reported
a 60% decrease in the number of hospitalizations (Španiel et al.,
2008a, 2008b).
Although this research report indicated excellent results, it included
the following unclear issues. It was reported that the effectiveness
of relapse prevention was correlated with the subject's response
rate to the questions and had the added restriction of not under-
standing the actual state of pharmacological intervention when in
a warning state. Consequently, it is unclear whether the relapse
prevention effectiveness of the ITAREPS only reﬂects the psycho-
educational effectiveness or differences in user adherence to the pro-
tocol of the program such as the response rate to the questions or
whether increasing medication during the warning state is impor-
tant (Volavka, 2008).
In this study, we employed visiting nurses, wherein one of their
basic tasks in Japan is to check patient'smedication compliance andpsy-
chiatric condition for prevention of relapse when they visit his/her
home, and were asked to perform one part of this relapse prevention
program to exclude the effects of user adherence. More speciﬁcally, vis-
iting nurses were asked to question patients through phone calls rather
than a SMS. Consequently, we were able to obtain reliable responses
from all patients regardless of their adherence. We also prescribed
20% of the baselinemaintenance dose of antipsychotic drugs to patients
in advance, for a quick and reliable increase in their dose during the
ALERT PERIOD regardless of whether patients undergo medical exami-
nation. Furthermore, the visiting nurses veriﬁed that the patient had
increased their oral medication during the ALERT PERIOD by visiting
patient's home directly. The objective of this study was to verify the
effectiveness of the ITAREPS in preventing relapses by performing a ran-
domized controlled trial using the ITAREPS that was not inﬂuenced by
the effect of user adherence to the protocol.2. Methods
2.1. Trial design
This trial was a multicenter, prospective, open-labeled, randomized
controlled trial. The trial was carried out at four institutions (Chiba
University Hospital, Shizuoka Psychiatric Medical Center, Iida Hospital,
and Matsubara Hospital) across Japan and was approved by the ethics
committee of each institution. Subjects were recruited from March to
July 2010, and each subject was observed for 12 months.
2.2. Subjects
The subjects were outpatients at the institutions cooperating in the
trial. The selection criteria included 20–65-year-old patients diagnosed
with schizophrenia deﬁned by the Diagnostic and Statistical Manual of
Mental Health Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
criteria, those who were receiving an oral antipsychotic drug, those
who had a landline or mobile phone, and those who had a history of
hospitalization due to worsening of psychiatric symptoms. All patients
provided their written informed consent. The exclusion criteria includ-
ed patients with a history of other mental illnesses without any compli-
cations, those not suffering from organic brain disease or other serious
mental illnesses, and those diagnosed by a doctor to be at risk of suicide
when consent was provided.
2.3. Randomization
The administrators at each institution whowere independent of the
evaluators and physicians administering treatment carried out the ran-
domization. The administrators only knew the patient's code number,
name, date of birth, and stratiﬁcation criteria. They allocated patients
using a minimization method that adjusted imbalances in the subject's
background at the start of the study.
2.4. Measurement items
Wemeasured the number of rehospitalizations on the basis of wors-
ening of psychiatric symptoms, the period until rehospitalization, and
the total number of rehospitalization days in each group. We also used
the Brief Psychiatric Rating Scale (BPRS) to assess psychiatric symp-
toms, and recorded changes in the total BPRS score at the time of
rehospitalization after the start of the trial. Furthermore, we considered
relapses based on worsening of psychiatric symptoms that did not re-
quire hospitalization. The deﬁnition of relapse is not ﬁxed; it has been
deﬁned in several ways in other studies (Gleeson et al., 2010). In this
study, if a doctor decided during a routine examination that there had
been a relapse due to worsening of psychiatric symptoms, all relapses
and changes in the total BPRS score from the start of the trial were
recorded. The subject's voluntary adverse effect reports were collected
during each routine examinationwhile performing clinical assessments.
2.5. Intervention
Subjects were randomized into an ITAREPS group and a control
group. Visiting nurses asked the subjects in both groups about each
itemof the EWSQ through phone calls weekly, in order to exclude the ef-
fects of user adherence to the protocol. After visiting nurses questioned
the subjects in the ITAREPS group, visiting nurses input the subjects'
answers into a computer, which automatically assessed the subjects'
answers according to a given score threshold anddetected earlywarning
signs.When early warning signswere detected, subjects were prompted
by visiting nurses through phone call to take additional medications
prescribed in advance (20% of the baselinemaintenance dose of antipsy-
chotic drugs) within the next 24 h. Visiting nurses also visited patients'
home to veriﬁed that subjects had indeed increased their oralmedication
Table 1
The demographic and baseline characteristics.
ITAREPS group
(n = 22)
Control group
(n = 23)
p
Gender, n male:female 12:10 13:10 1.00a
Family member participation, n Yes:No 18:4 19:4 1.00a
Age, years (mean ± SD) 42.3 ± 11.8 44.0 ± 9.3 0.54b
Age at onset, years (mean ± SD) 25.5 ± 8.7 24.7 ± 9.0 0.79b
Illness duration, years (mean ± SD) 16.9 ± 11.6 19.3 ± 9.6 0.25b
Baseline total BPRS score (mean ± SD) 15.6 ± 8.9 17.9 ± 7.8 0.27b
Period after last hospital discharge, months
(mean ± SD)
35 ± 61 46 ± 51 0.44b
ITAREPS = InformationTechnologyAidedRelapse Prevention Programme in Schizophrenia.
SD = standard deviation.
BPRS = Brief Psychiatric Rating Scale.
a Fisher's exact test.
b Mann–Whitney U test.
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symptoms, recommending earlymedical examinations, etc.). In the con-
trol group, the visiting nurses assessed the answers by the subjects
through phone calls and predicted relapses. The nurses were instructed
to conduct nursing care visits as usual, whether or not they predicted
relapses.
2.6. Statistical analysis
The ITAREPS and control groups were compared by performing an
intention-to-treat analysis that included all group-allocated subjects.
Fisher's exact test and the Mann–Whitney U-test were used for the
baseline comparison based on the quality of the data, number of
rehospitalizations, average number of rehospitalization days, number
of inpatient days on each rehospitalization, and a comparison of the
number of relapses. The Kaplan–Meier method and the log-rank test
were used to analyze the comparisons between the two groups during
the time after randomization to rehospitalization. Hazard ratio was
calculated using a proportional hazard analysis to determine the
rehospitalization rates in the two groups. Comparisons of the changes
in the total BPRS scores were analyzed using an analysis of covariance
considering the score at the start of the trial. Statistical signiﬁcance
was set at p b 0.05. Statistical analysis was performed with SPSS for
Windows version 19.0 (SPSS Inc., Chicago, IL, USA).
3. Results
Of the 399 potential participants who met the participation criteria,
received an explanation of the study, and provided their consent in
writing, 45 were randomized to the ITAREPS group (n = 22) and con-
trol group (n = 23). Approximately 10% of the subjects of each group
withdrew from the trial for reasons other than rehospitalization due
to worsening of psychiatric symptoms. We performed an intention-to-
treat analysis on the results, including cases of subject drop-outs dueScreening (n=399
Randomization (n=
Analysis subjects (n=22)
Carry out (n=18)
Discontinue (n=4)
- Rehospitalization due to worsening of
psychiatric symptoms (n=2)
- Rehospitalization due to physical illness (n=1)
- Patient convenience (n=1)
ITAREPS group (n=22)
Fig. 1. Enrollment, randomization, andto hospitalization for physical illness and for their own convenience
(Fig. 1). The background elements for the subjects in each group at
the start of the trial are shown in Table 1. Group characteristics were
almost the same. The computer made 1111 automatic assessments in
the ITAREPS group, among which signs of relapse according to EIA
were detected 75 times. No adverse effects were reported by researchers
or subjects.
3.1. Period until rehospitalization and the number of rehospitalization days
Two rehospitalizations were observed during the 12 months for the
22 patients in the ITAREPS group (9.1%), and eight rehospitalizations
were observed for the 23 patients in the control group (34.8%). The
average period until rehospitalization was calculated using the Kaplan–
Meier method using the log-rank test and was signiﬁcantly longer in
the ITAREPS group than in the control group (log rank, 4.53, p = 0.033))
Excluded (n=354)
Does not meet trial participation criteria (n=336)
Participation refused (n=18)
45)
Analysis subjects (n=23)
Carry out (n=12)
Discontinue (n=11)
- Rehospitalization due to worsening of 
psychiatric symptoms (n=8)
- Patient convenience (n=3)
Control group (n=23)
follow-up of the study patients.
Days after randomization
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+ Censored subjects
ITAREPS group
Control group
p=0.033 by the log-rank test
Fig. 2. Time to rehospitalization after randomization.
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compared with the control group (hazard ratio = 0.21, 95% conﬁdence
interval (CI) 0.04–0.99, p = 0.049; number needed to treat (NNT) = 4,
95% CI 2.1–35.5). The total number of rehospitalization days was signiﬁ-
cantly lower in the ITAREPS group (37 days) compared with the control
group (710 days) (p = 0.023). The number of inpatient days on each
rehospitalization was also signiﬁcantly lower in the ITAREPS group
(18.5 days) compared with the control group (88.8 days) (p = 0.036)
(Table 2).
3.2. Number of relapses and changes in total BPRS score
Seven relapses including rehospitalization during the 12 months of
observation occurred in the 22 patients in the ITAREPS group and nine
relapses occurred in the 23 patients in the control group, with no statis-
tically signiﬁcant differences. However, the ratio of the number of
rehospitalizations to that of relapses was signiﬁcantly lower in the
ITAREPS group than in the control group (p = 0.035). No statistically
signiﬁcant differences were observed for the mean change in total
BPRS scores at rehospitalization in either group. However, the mean
change in total BPRS scores at relapse was less in the ITAREPS group,
changing by 11.3 points compared with 17.2 points in the control
group, with a signiﬁcant difference observed using the analysis of
covariance adjusted with the baseline score (p = 0.019) (Table 2).
4. Discussion
We obtained signiﬁcantly good results in the ITAREPS group for the
average period until rehospitalization and the total number of daysTable 2
Results at 12 months.
ITAREPS group
(n = 22)
Control group
(n = 23)
p
Number of hospitalizations 2 8 0.071a
Total number of rehospitalization days 37 710 0.023b, ⁎
Inpatient days (mean ± SD) 18.5 ± 12.0 88.8 ± 57.0 0.036b, ⁎
Number of relapses 7 9 0.758a
Number of rehospitalizations/number
of relapses
2/7 8/9 0.035a, ⁎
Change in total BPRS scores at
rehospitalization (mean ± SD)
9.0 ± 1.4 18.3 ± 6.1 0.135c
Change in total BPRS scores at relapse
(mean ± SD)
11.3 ± 5.6 17.2 ± 6.5 0.019c, ⁎
ITAREPS = InformationTechnologyAidedRelapse PreventionProgramme in Schizophrenia.
SD = standard deviation.
BPRS = Brief Psychiatric Rating Scale.
a Fisher's exact test.
b Mann–Whitney U test.
c Analysis of covariance.
⁎ p b 0.05.hospitalized. No contradictions or large changes were observed in com-
parison with the results of previous studies reported by Španiel et al.
(2008a, 2008b). No signiﬁcant differences were observed for the num-
ber of rehospitalizations, but statistical power may have been low due
to the insufﬁcient sample size and short observation period. The hazard
ratiowas calculated to be 0.21 (p = 0.049; 95%CI, 0.04–0.99) in the two
groups, indicating that the risk of rehospitalization was reduced by
approximately one-ﬁfth after introducing the ITAREPS. Visiting nurses
were used in this study to prevent the inﬂuence of user adherence,
and nurses were instructed to perform interventions using routine
nursing care (checking symptoms, recommending early medical exam-
inations, etc.) during relapses in the control group because of ethical
considerations. An even larger difference may have been observed if
no intervention was performed during a relapse in the control group.
The risk ratio of rehospitalization prevention effectiveness was 0.71 in
a systematic review that covered the effect of psychoeducation (Xia
et al., 2011), and the adjusted hazard ratio in studies examining the
effect of switching from oral antipsychotics to sustainable injectable
formulations was 0.36 (Tiihonen et al., 2011). The relapse prevention
effectiveness of the ITAREPS was relatively large compared with these
other methods; however, conditions differed between studies, thus
making the results difﬁcult to compare.
Answers to questions were reliably obtained and drug interventions
were performed during warning states because visiting nurses per-
formed a part of the ITAREPS in this study. Consequently, the effects
of not only patient adherence but also practitioner adherence to the
protocol could be excluded. Many cases wherein medication was not
increased during the warning condition occurred in randomized con-
trolled trials recently carried out by Španiel et al. The adherence of prac-
titioners providing treatment became a hindrance, and no differences
were found in the intention-to-treat analysis (Španiel et al., 2012). In
this study, the effectiveness was veriﬁed, and we excluded the effects
of user adherence so that an intervention that involved early detection
of signs of relapse and earlymedication increases conﬁrmed the relapse
prevention effectiveness of the ITAREPS. Furthermore, we believe that
stable relapse and rehospitalization prevention effectiveness not in-
ﬂuenced by user adherence can be achieved by devising methods
according to the local medical resources provided, such as the visiting
nurses who performed a part of the ITAREPS in this study.
We found that the number of relapses in the ITAREPS groupwas the
same as that in the control group, but the ratio of the number of
rehospitalizations to that of relapses was signiﬁcantly lower in the
ITAREPS group than in the control group. The mean change in total
BPRS scores at relapse and the number of inpatient days on each
rehospitalization were also signiﬁcantly lower in the ITAREPS group.
Thus, the ITAREPS detected signs of relapse and prevented aggravation
during relapse by increasing medication, which shortened the relapse
duration. We postulate that the ITAREPS is an effective intervention
during the early stages of relapse.
Antipsychotic drug therapy causes a dilemma during the mainte-
nance phase of schizophrenia. Althoughmany treatment guidelines rec-
ommend continuing antipsychotic drug therapy to prevent relapses, a
smaller amount of medication may be preferable considering the well-
known side effects such as extrapyramidal symptoms due to antipsy-
chotic drugs and the adverse effects of the antipsychotic drugs on the
brain (Ho et al., 2011). The ITAREPSwas effective in preventing relapses
through a temporary increase in medication during the early relapse
phase. Therefore, in the future, it may have a large effect on treatment
strategies during the maintenance phase wherein the above dilemma
is faced.
5. Conclusion
This study noted that the relapse prevention effectiveness of the
ITAREPS for schizophrenia was high, and we conﬁrmed that the
ITAREPS, i.e., detecting signs of relapse and increasing medication
244 H. Komatsu et al. / Schizophrenia Research 150 (2013) 240–244during the warning state, is an effective intervention during the early
stages of relapse.
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